PT-141 (bremelanotide) is an FDA-approved prescription treatment for women with low sexual desire. It works in the brain, not in your hormones, making it a distinct option for women who have been diagnosed with hypoactive sexual desire disorder (HSDD).
1. What Is PT-141?
PT-141 is the common name for bremelanotide, a synthetic peptide that targets the central nervous system to increase sexual desire. The FDA approved it in June 2019 under the brand name Vyleesi, specifically for premenopausal women with acquired, generalized HSDD not caused by a medical condition, relationship issues, or medication side effects.
Unlike most sexual wellness treatments you may have heard about, PT-141 does not work by changing your hormone levels. It acts directly on the brain’s desire pathways, which is what sets it apart from hormonal therapies.
At Telezen MD, PT-141 is offered as part of our women’s sexual wellness program, prescribed by our licensed medical team and compounded by a 503A FDA-regulated pharmacy. If you are curious about PT-141 for men, you can learn more on our PT-141 for men page.
2. How PT-141 Works in the Body
PT-141 is a melanocortin receptor agonist. It binds to melanocortin-4 receptors (MC4R) concentrated in the hypothalamus, the brain region responsible for regulating sexual behavior. When these receptors are activated, they trigger a release of dopamine in the brain’s reward and motivation pathways.
Dopamine is the neurochemical of desire. By increasing dopamine signaling in these specific pathways, PT-141 produces a genuine increase in sexual wanting. This is not a physical arousal mechanism like blood flow. It is a neurological one.
The result is that women who use PT-141 often report an increase in sexual interest, spontaneous desire, and overall motivation for intimacy, starting within 30 to 60 minutes of the injection.
3. PT-141 vs. Hormonal Treatments: What’s the Difference?
Women dealing with low libido often consider hormonal options like estrogen or testosterone therapy. These have real benefits for the right candidates. But PT-141 works through an entirely different pathway, and that distinction matters.
| PT-141 (Bremelanotide) | Hormonal Treatments (HRT/Testosterone) | |
|---|---|---|
| How It Works | Activates melanocortin receptors in the brain | Adjusts estrogen, progesterone, or testosterone levels |
| Target | Central nervous system (desire pathways) | Endocrine system (hormone levels) |
| Addresses | Low desire / libido directly | Hormonal imbalances; libido as secondary benefit |
| FDA Status | Approved (Vyleesi) for premenopausal HSDD | Approved for various menopausal/hormonal conditions |
| Dosing | On-demand injection, ~45 min before intimacy | Daily or as prescribed (patches, creams, pills) |
| Onset | 30-60 minutes | Weeks to months for full effect |
PT-141 does not change your hormone levels. It does not require ongoing titration of hormones or long weeks of waiting to see a result. You use it on-demand, when you want it, and the effect begins within the hour.
For women whose hormone levels are already balanced but who still experience low desire, PT-141 addresses the gap that hormonal therapy alone may not fill.
4. FDA Approval: What the Clinical Trials Found
The FDA approval of Vyleesi (bremelanotide) was based on two Phase 3 clinical trials involving premenopausal women with HSDD. The key findings include:
- Increased desire: Women taking bremelanotide showed statistically significant improvements in sexual desire scores compared to women on placebo.
- Reduced distress: Participants also reported meaningful decreases in the personal distress caused by their low desire, a core component of the HSDD diagnosis.
- Sustained results: A 52-week safety study confirmed that the treatment continued to be well-tolerated with consistent results over time.
The FDA specifically approved bremelanotide for women with acquired HSDD (desire that diminished after a period of normal function) that is generalized (not situation-specific or limited to a particular partner). This is the clinical profile PT-141 was designed for.
5. Dosage and How to Use PT-141
How It’s Administered
PT-141 is given as a subcutaneous injection, meaning a small injection just under the skin, typically into the abdomen or upper thigh. The injection is done with a fine-gauge insulin-type syringe and is virtually painless.
Timing
You inject PT-141 approximately 45 minutes before anticipated sexual activity. Effects typically begin within 30 to 60 minutes and can last anywhere from 6 to 24 hours depending on the individual.
Frequency
PT-141 is an on-demand medication, not a daily treatment. Per FDA labeling, you should not exceed one dose in any 24-hour period, and no more than eight doses per month. Using it more frequently increases the risk of side effects without adding additional benefit.
6. What to Expect After Using PT-141
Most women notice a shift in desire or interest within the first hour. Some describe it as a natural pulling-in of attention toward intimacy. Others simply feel more receptive and open than they have in some time.
PT-141 does not force arousal. It does not work if there is no desire present at all. Think of it as lowering the threshold, not flipping a switch. The best results tend to come when there is already some baseline attraction or interest that has simply been muted.
Results vary between individuals. Some women find the first dose very effective, while others notice more benefit after a few uses as their body adapts.
7. Side Effects and Who Should Avoid PT-141
Common Side Effects
- Nausea (~40%): The most common side effect. It is usually mild, peaks around two hours after injection, and resolves within a few hours. Taking the injection with a light snack and staying hydrated can help.
- Flushing (~20%): A warm, flushed feeling in the face and neck. It is harmless and temporary, typically resolving within a few hours.
- Headache (~12%): Generally mild and manageable with standard over-the-counter pain relief.
- Injection-site reactions: Minor redness or irritation at the injection site that resolves quickly. Rotating the injection site helps.
- Temporary blood pressure increase: PT-141 can cause a transient rise in blood pressure that typically normalizes within 12 hours.
Who Should Not Use PT-141
PT-141 is not appropriate for everyone. You should not use it if you have uncontrolled high blood pressure, active cardiovascular conditions, or if you are pregnant or nursing. Your Telezen medical team will review your health history before prescribing to ensure it is safe for you.
8. Who Is PT-141 For?
PT-141 is best suited for women who experience low sexual desire that causes personal distress and does not have a clear underlying cause such as relationship problems, unmanaged depression, or medication side effects.
Specifically, good candidates include:
- Premenopausal women with HSDD: This is the FDA-approved indication. If you have been diagnosed with, or suspect you have, hypoactive sexual desire disorder, PT-141 is one of the few treatments with direct clinical evidence.
- Women whose hormones are balanced but libido remains low: If you are already on hormone therapy and still not feeling desire, PT-141 targets the neurochemical side of the equation that hormones alone may not address.
- Women who want an on-demand option: Unlike daily medications, PT-141 is used only when you want it. There is no daily pill or patch to manage.
PT-141 is not a treatment for stress, relationship issues, depression, or physical pain during intimacy. These require different approaches, and your Telezen provider can help identify the right path for your specific situation.
9. How to Get PT-141 Through Telezen MD
At Telezen MD, getting started with PT-141 is straightforward and handled entirely online. There is no need to travel to a clinic or schedule an in-person visit.
Here is how the process works:
- Complete your intake: Fill out a detailed medical history form online. This includes information about your current symptoms, health history, and any medications you are taking.
- Choose your plan: Review your sexual wellness options and select the plan that fits your needs.
- Submit your intake: Your completed intake goes directly to our licensed medical team for review.
- Medical review within 24 hours: A licensed provider reviews your intake and, if PT-141 is appropriate for you, issues a prescription. You will hear back within 24 hours.
- Medication ships to your door: Your PT-141 is compounded by a 503A FDA-regulated pharmacy and shipped directly to you, with clear instructions for use.
All PT-141 prescribed through Telezen MD is compounded by 503A FDA-regulated pharmacies. You will never receive research-grade or unverified products.
Ready to get started? Visit our PT-141 page to learn more and begin your intake.
Frequently Asked Questions About PT-141 for Women
Is PT-141 FDA-approved for women?
Yes. The FDA approved bremelanotide under the brand name Vyleesi in June 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). This makes it one of only a small number of FDA-approved treatments targeting female sexual desire. PT-141 compounded by a 503A pharmacy is not itself FDA-approved, but is prescribed from a licensed provider and sourced from a regulated pharmacy.
How is PT-141 different from hormonal treatments for low libido?
Hormonal treatments like estrogen or testosterone work through the endocrine system by adjusting hormone levels. PT-141 works through the central nervous system, activating melanocortin receptors in the brain to increase dopamine in desire pathways. It does not change your hormone levels at all. This is why PT-141 can be effective even for women whose hormones are already balanced.
How quickly does PT-141 work?
PT-141 typically begins working within 30 to 60 minutes of injection. The recommended timing is about 45 minutes before anticipated sexual activity. Effects can last from 6 to 24 hours depending on the individual.
What are the main side effects of PT-141 in women?
The most common side effects are nausea (about 40% of users), facial flushing (about 20%), and headache (about 12%). These are generally mild and temporary. A transient increase in blood pressure is also possible. PT-141 is not recommended for women with uncontrolled high blood pressure or active cardiovascular conditions.
Can I use PT-141 every day?
No. PT-141 is an on-demand treatment, not a daily medication. You should not exceed one dose per 24-hour period or more than eight doses per month, per FDA labeling. Using it more frequently increases side effect risk without adding benefit.
Does Telezen MD offer PT-141 for men as well?
Yes. While this article focuses on PT-141 for women, Telezen MD also offers PT-141 for men as a libido and sexual wellness treatment. You can learn more on the Telezen PT-141 for men page.
The Bottom Line
If low sexual desire is something you have been struggling with, and it is causing you real distress, you deserve a real solution. PT-141 is the only FDA-approved treatment that targets sexual desire directly at the brain level, and it is now available through Telezen MD’s online medical program.
You do not need to normalize a low libido that is affecting your well-being or your relationships. Our licensed medical team is here to review your intake, answer your questions, and help you decide whether PT-141 is right for you.
Visit our PT-141 page to learn more, or start your intake today and hear back from our team within 24 hours.
Sources
- U.S. Food and Drug Administration. Vyleesi (bremelanotide) prescribing information. 2019. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-vyleesi
- Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019;134(5):899-908. https://pubmed.ncbi.nlm.nih.gov/31599840/
- Simon JA, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstetrics & Gynecology. 2019;134(5):909-917. https://pubmed.ncbi.nlm.nih.gov/31599841/
- Diamond LE, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141). Journal of Sexual Medicine. 2006;3(4):628-638. https://pubmed.ncbi.nlm.nih.gov/16839318/
- Cleveland Clinic. Bremelanotide Injection. https://my.clevelandclinic.org/health/drugs/21312-bremelanotide-injection
Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Telezen MD services are available only to patients who qualify following an online medical evaluation with a licensed healthcare provider. Results vary by individual. Compounded medications prescribed through Telezen MD are compounded by 503A FDA-regulated pharmacies. Compounded medications are not reviewed or approved by the FDA for safety or efficacy. Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any new medical treatment. If you experience any adverse effects, contact your provider immediately.
